Carisma Therapeutics Inc. (CARM) Financial Statements (2024 and earlier)

Company Profile

Business Address 3675 MARKET STREET
PHILADELPHIA, PA 19104
State of Incorp. PA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:77,600166,900162,63652,38948,12150,422
Cash and cash equivalents77,605112,553162,63652,38948,12150,422
Short-term investments  54,366    
Other undisclosed cash, cash equivalents, and short-term investments(5)(19)    
Restricted cash and investments  21,000 3,000  
Receivables  82524,493   
Prepaid expense      
Deposits current assets      
Other undisclosed current assets2,87141918,4767,4786,3261,334
Total current assets:80,471189,144205,60562,86754,44751,756
Noncurrent Assets
Operating lease, right-of-use asset2,173    
Property, plant and equipment   43123238321
Intangible assets, net (including goodwill)   27,76459,46459,46459,464
Goodwill   13,06413,06413,06413,064
Intangible assets, net (excluding goodwill)   14,70046,40046,40046,400
Prepaid expense   7,192   
Restricted cash and investments  3020202020
Other noncurrent assets   123349196 
Other undisclosed noncurrent assets6,910     
Total noncurrent assets:9,0833035,14259,95659,91859,805
TOTAL ASSETS:89,554189,174240,747122,823114,365111,561
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,59530,86911,1087,0758,0716,113
Accounts payable3,9331,2332,8533,1021,9021,367
Accrued liabilities7,66229,6368,2553,9736,1694,746
Deferred revenue1,413  1,500 
Debt544     
Other liabilities965115460489446 
Other undisclosed current liabilities1,391  8,985  
Total current liabilities:15,90830,98411,56818,0498,5176,113
Noncurrent Liabilities
Long-term debt and lease obligation328     
Finance lease, liability328    
Liabilities, other than long-term debt46,786 57,469114,001132,54848,713
Deferred revenue45,000 1,5001,500 
Deferred income tax liabilities   3,96912,52812,528
Other liabilities926  118 313
Operating lease, liability860    
Business combination, contingent consideration, liability   52,00099,855120,02048,400
Total noncurrent liabilities:47,114 57,469114,001132,54848,713
Total liabilities:63,02230,98469,037132,050141,06554,826
Equity
Equity, attributable to parent26,532158,190171,710(9,227)(26,700)44,207
Common stock4020219914010777
Additional paid in capital271,594494,675487,768306,554266,717230,154
Accumulated other comprehensive loss  (546)    
Accumulated deficit(245,102)(336,141)(316,257)(315,921)(293,524)(186,024)
Total equity:26,532158,190171,710(9,227)(26,700)44,207
Other undisclosed liabilities and equity      12,528
TOTAL LIABILITIES AND EQUITY:89,554189,174240,747122,823114,365111,561

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues14,90040,00026,54411,236  
Gross profit:14,90040,00026,54411,236  
Operating expenses(103,650)(65,909)(35,093)(32,313)(108,491)(34,500)
Other undisclosed operating income19     
Operating loss:(88,731)(25,909)(8,549)(21,077)(108,491)(34,500)
Nonoperating income (expense)  2,150(60)125991807
Investment income, nonoperating  1,854    
Other nonoperating income (expense)  296(60)125991807
Interest and debt expense(139)     
Loss from continuing operations before income taxes:(88,870)(23,759)(8,609)(20,952)(107,500)(33,693)
Income tax expense (benefit) 3,8758,273(1,445)  
Other undisclosed income from continuing operations      
Loss from continuing operations:(88,870)(19,884)(336)(22,397)(107,500)(33,693)
Loss before gain (loss) on sale of properties:(336)(22,397)(107,500)(33,693)
Other undisclosed net income1,991     
Net loss attributable to parent:(86,879)(19,884)(336)(22,397)(107,500)(33,693)
Preferred stock dividends and other adjustments    (147)  
Net loss available to common stockholders, diluted:(86,879)(19,884)(336)(22,544)(107,500)(33,693)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(86,879)(19,884)(336)(22,397)(107,500)(33,693)
Comprehensive loss:(86,879)(19,884)(336)(22,397)(107,500)(33,693)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent41(546)    
Comprehensive loss, net of tax, attributable to parent:(86,838)(20,430)(336)(22,397)(107,500)(33,693)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: